Exhibiting at FOOD INGREDIENTS CHINA 2025

Suzhou Yixi Biotechnology Co., Ltd. (苏州一兮生物技术有限公司), headquartered in Suzhou, China, is a pioneering high-tech enterprise focusing on the research, development, and industrial application of synthetic biotechnology. Specializing in human milk oligosaccharides (HMOs) and microbial proteins, the company has emerged as one of China’s front-runners in the application of synthetic biology in the food and health sectors.

Core Business and Product Portfolio

Yixi Biotechnology primarily operates in two major domains:

• Food-grade Additives:
  • Human Milk Oligosaccharides (HMOs), including 2'-Fucosyllactose (2'-FL), 3-Fucosyllactose (3-FL), Lacto-N-tetraose (LNT), and others.
• Feed-grade Additives:
  • Microbial protein products aimed at replacing traditional protein sources in aquaculture and livestock feeds.

These biotechnology-derived products play a crucial role in gut health, immunity development, and sustainable protein alternatives, serving industries such as infant nutrition, dietary supplements, functional foods, and animal nutrition.

Specialisation and Unique Value Proposition

The company’s unique edge lies in its mastery of synthetic biology, metabolic engineering, and fermentation technologies. Yixi's R&D has enabled:

• High-yield strains of engineered microorganisms for the cost-effective production of HMOs.
• Customized formulation of oligosaccharide blends to mimic natural human milk composition.
• Sustainable production methods for microbial proteins, reducing dependence on animal-based sources.

Yixi's integrated production model — from strain development to downstream purification — ensures competitive pricing and scalable quality control.

Financials and Global Presence

While Suzhou Yixi is a privately held company and specific revenue figures are not publicly disclosed, market intelligence from Chinese biotech platforms and investor briefings indicate:

• Estimated annual revenue exceeding RMB 100 million (approx. USD 14 million) as of 2023.
• Strategic expansion to North American and European markets, where HMOs are gaining regulatory approvals.
• Successful funding rounds from institutional investors focused on biotech and sustainability sectors.

Export and Shipment Records

Though the company is still growing its international logistics footprint, data from Chinese export monitoring platforms indicate:

• Initial commercial shipments of HMOs to Southeast Asian countries began in 2022.
• Ongoing regulatory registration processes for the EU and US markets.
• Partnerships with global infant nutrition companies for HMO supply trials.

Certifications and Compliance

Suzhou Yixi places a strong emphasis on regulatory compliance and quality assurance. The company has acquired:

• FSSC 22000 Food Safety System Certification
• ISO 9001:2015 Quality Management System
• Halal and Kosher certifications
• HMOs under active application for GRAS (Generally Recognized as Safe) status in the United States

Their products meet China's GB standards for food and feed safety, and the company is preparing dossiers for EFSA and FDA submission for broader market access.

Target Market

Yixi Biotechnology’s primary markets include:

• Infant formula manufacturers
• Dietary and functional food brands
• Animal feed and aquaculture companies
• B2B ingredients suppliers in nutraceutical sectors

With the rising global demand for functional prebiotics and sustainable proteins, Yixi’s core offerings are well aligned with evolving consumer and regulatory trends.

Capabilities and Infrastructure

• 100,000+ square feet fermentation and production facility in Suzhou Industrial Park
• Automated downstream purification lines for HMOs with GMP compliance
• Dedicated R&D and pilot-scale labs with partnerships with top Chinese universities
• In-house QC labs equipped with HPLC, LC-MS/MS, and NMR technologies
• Annual production capacity exceeding 100 metric tons of HMOs

The company continues to expand its production footprint to meet growing demand, both domestically and internationally.

Industry Recognition and Partnerships

Suzhou Yixi has been recognized as:

• High-Tech Enterprise by Jiangsu Province
• Recipient of Innovation Fund for Small Technology Enterprises by the Ministry of Science and Technology
• Strategic partner in national food security and synthetic biology innovation projects

Yixi is also a member of China’s Synthetic Biology Industry Alliance and has received grants for biomanufacturing scale-up.

Customer Endorsements

Though customer names are confidential, public feedback from industrial collaborators includes:

“Yixi's 2’-FL demonstrated excellent purity and performance in our pilot formula. Their team was highly responsive and technically strong.”
— R&D Head, Infant Nutrition Brand (Asia-Pacific)

Major Achievements

• Developed China’s first fully localized production pipeline for multiple HMOs
• Successfully scaled cost-competitive microbial protein for aquatic feed applications
• Filed over 20 patents related to microbial strain engineering and bioprocess optimization
• Initiated international regulatory pathways for broader market penetration

Suzhou Yixi Biotechnology continues to bridge the gap between cutting-edge science and industrial applications, reinforcing China’s position in the global synthetic biology landscape.